EMB-01
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
Trial Timeline
Oct 21, 2021 → Dec 31, 2025
NCT ID
NCT05176665About EMB-01
EMB-01 is a phase 1/2 stage product being developed by LabCorp for Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05176665. Target conditions include Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05176665 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| LY4337713 | Eli Lilly | Phase 1 | 33 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant | Eli Lilly | Phase 3 | 77 |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg | Vincerx Pharma | Phase 1 | 25 |
| VIP236 (Q3W) + VIP236 (Q2W) | Vincerx Pharma | Phase 1 | 25 |
| GEMZAR + ALIMTA | Eli Lilly | Phase 3 | 77 |